Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Company through profitability; proforma cash approaching $800 million as of June 30WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo™ (axati ...

WALTHAM, Mass., Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA with a fireside chat on Wednesday, November 13, 2024, at 1:30 p.m. ...

WALTHAM, Mass., Oct. 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercialstage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 5, 2024. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, November 5, 2024 to discuss the Company's financial ...

"plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materi ...

Syndax Pharmaceuticals (SNDX) closed the last trading session at $23.50, gaining 18.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35.31 indicates a 50.3% upside potential. The average comprises 13 short-term price targets ranging from a low of $23 to a high of $45, with a standard deviation of $6.28. While the lowest estimate indicates a decline of 2.1% from the current price ...

WALTHAM, Mass., July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2024 financial results and provide a business update on Thursday, August 1, 2024. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, August 1, 2024 to discuss the Company's financial r ...

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. Here's What You Should Know About Analysts' Price Targets They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other w ...

"Pyxis Oncology's novel ADC approach and impressive pipeline comprised of next-generation therapeutics are aimed to target difficult-to-treat cancers and improve the quality of life of patients," said Mr. Metzger. "I look forward to working with the deeply experienced board and leadership team assembled at Pyxis Oncology to further advance the Company's mission of improving outcomes for patients with cancer." Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. T ...

– IDMC recommendation to advance based on favorable safety profile observed in Phase 1a portion of trial – WALTHAM, Mass., June 6, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has advanced into the Phase 1b portion of its Phase 1/2 proof-of-concept trial of revumenib, the Company's highly selective, oral menin inhibitor, as a monotherapy in patients with relapsed or refrac ...

Core Insights - Syndax Pharmaceuticals granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees under the Company's 2023 Inducement Plan [1] - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting monthly thereafter [1] Company Overview - Syndax is a clinical-stage biopharmaceutical company focused on developing an innovative pipeline of cancer therapies [2] - Key products in the pipeline include revumenib, a selective menin inhibitor, and axatilimab, a monoclonal antibody targeting the CSF-1 receptor [2]